A world-first study could help revolutionise the treatment of brain cancer, researchers say.
The research will trial multiple new treatments for people in the UK living with an aggressive form of brain cancer called glioblastoma.
Glioblastomas are fast-growing and aggressive tumours and are the most common type of primary brain cancer in adults.
The study will, for the first time, enable researchers to adapt treatments to people in the trial, meaning multiple new drugs can be tested in a short period.
As part of the study, every patient will also have their genome sequenced – which determines their genetic makeup – allowing researchers to target their treatment with greater precision.
Michelle Mitchell, chief executive of Cancer Research UK, said: “Brain tumours are notoriously hard to treat because we still don’t know enough about the biology of the disease, and current treatments are not effective enough.
“This new trial offers something different because researchers will use the DNA of participants to help them target treatments. Whole genome sequencing tests can give clues about how a cancer may have developed, how it will behave and what treatment options would work best.
“More research is needed, but it is hoped that the technology could one day be used within the NHS to improve the treatment and care of people with cancer.”
Because of the biology of the brain, finding new treatments for glioblastoma has been difficult.
Over the past two decades there have been 1,000 brain cancer clinical trials, but none has resulted in significant breakthroughs.
To help address this, Cancer Research UK and Australian charity Minderoo Foundation have each committed £1.68 million (£3.36 million total) to fund the “next-Generation aGile Genomically Guided Glioma platform trial”, also known as the 5G platform trial.
Experts hope the trial will help speed up the development of new treatments while benefitting patients.
In the study, the drug or combination of drugs a patient receives will be based on the specific genetic makeup of their cancer.
The trial design also allows treatments developed for other types of cancer to be tested in patients with brain cancer for the first time.
The 5G platform trial is sponsored by The Institute of Cancer Research, London, and conducted by the Joint Drug Development Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR).
Honorary consultant neurosurgeon at Cambridge University Hospitals NHS Foundation Trust and co-lead of the Brain Cancer Virtual Institute at the Cancer Research UK Cambridge Centre, Dr Richard Mair, said: “Brain cancers like glioblastoma are notoriously difficult to treat.
“I am excited to co-lead this world-first trial designed with this cancer type in mind.
“The use of whole genome sequencing for every patient on the trial performed in ‘real time’ enables us to be both agile and precise in our drug targeting.
“We hope that this approach will help patients with this cancer of unmet need.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereLast Updated:
Report this comment Cancel